Extreme drug resistance in primary brain tumors: In vitro analysis of 64 resection specimens

Journal of Neuro-Oncology

Volumn 58, Issue 2, 2002, Pages 115-123

  Haroun, R I ^a   Clatterbuck, R E ^a   Christopher Gibbons, M ^a   Burger, P C ^a   Parker, R ^b   Fruehauf, J P ^b   Brem, H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Oncotech Inc   (United States)

Author keywords

Brain tumors; Chemotherapy; Extreme drug resistance

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DOXORUBICIN; IRINOTECAN; PACLITAXEL; TOPOTECAN; VINCRISTINE;

ARTICLE; ASTROCYTOMA; BRAIN CANCER; CANCER GRADING; CANCER RESISTANCE; COMPARATIVE STUDY; CONTROLLED STUDY; EPENDYMOMA; GLIOBLASTOMA; HEMANGIOPERICYTOMA; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MENINGIOMA; OLIGODENDROGLIOMA; STATISTICAL ANALYSIS; WORLD HEALTH ORGANIZATION;

BRAIN NEOPLASMS; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; HUMANS;

EID: 0036069187     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016049111941     Document Type: Article

References (56)

1. Tumor chemosensitivity and chemoresistance assays
2. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo
3. Tumor chemosensitivity and chemoresistance assays
4. Predictive value of a single diagnostic test in unselected populations
5. Predictive tests for the response to cancer chemotherapy: Limitations related to the prediction of rare events
6. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposure
7. Correlations between therapeutic response of leukaemias as in-vitro drug-sensitivity assay
8. Prediction of individual response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model
9. The new WHO classification of brain tumors
10. Development of a minaturized, improved nucleic acid-precursor incorporation assay for chemosensitivity testing of human solid tumors
11. Primary bioassay of human tumor stem cells
12. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs
13. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia
14. Semi-micro adaptation of a 4-day differential staining cytotoxicity (DiSC) assay for determining the in vitro chemosensitivity of haematological malignancies
15. He's not going to talk about in vitro predictive assay again, is he?
16. The basis for current treatment recommendations for malignant gliomas
17. CCNU (1-(2-chloroethyl)-3-cylcohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer. Phase II study
18. Initial clinical trials with methyl-CCNU 1-(2-chlorethy)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU)
19. The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine
20. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
21. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma
22. Chemotherapy of malignant gliomas
23. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial
24. Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery
25. Clinical experience with vincristine (NSC-67574) in tumors of the central nervous system and other malignant diseases
26. Chemotherapy for malignant gliomas
27. Brain uptake and anticancer activities of vincristine and vinlastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in ras
28. Murine p-glycoprotein on stromal vessels mediates multidrug resistance in intracerebral human glioma xenografts
29. The blood-brain barrier efflux transporter as a detoxifying system for the brain
30. Phase II study of paclitaxel in patients wioth recurrent malignant glioma
31. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors
32. Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions. New approaches to brain tumor therapy central nervous system consortium
33. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas
34. Intravenous carboplatin for recurrent malignant glioma: A phase II study
35. Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure
36. Platinum analogues in the treatment of recurrent high grade astrocytoma
37. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors
38. Successful chemotherapy for recurrent malignant oligodendroglioma
39. Chemotherapy for anaplastic oligodendroglioma
40. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy
41. The treatment of anaplastic oligodendrogliomas and mixed gliomas
42. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
43. Oligodendroglioma: An appraisal of recent data pertaining to diagnosis and treatment
44. Salvage chemotherapy for recurrent malignant oligodendrogliomas
45. Hydroxyurea for treatment for unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway
46. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea
47. Chemotherapy for meningiomas
48. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B
49. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: A Southwest Oncology Group study
50. O6-alkylguanine-DNA alkyltransferase activity in human brain tumors
51. Inactivation of the DNA-repair igene MGMT and the clinical response of gliomas to alkylating agents
52. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas
53. Interstitial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery in the brain
54. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group
55. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study
56. Assumptions in the radiotherapy of glioblastoma